Skip to main content
Erschienen in: Diabetologia 7/2006

01.07.2006 | Review

Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria

verfasst von: R. I. G. Holt, R. C. Peveler

Erschienen in: Diabetologia | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

There is concern that antipsychotic drugs cause diabetes. Although there has been an explosion in the quantity of literature about this subject, it remains confusing and inconsistent. To assess whether the association between antipsychotic drugs and diabetes is causative, we applied the Austin Bradford Hill criteria to the available evidence. In support of a causative relationship, there is temporality for some cases of diabetes, and there is a biologically plausible explanation. The causative link between antipsychotic drugs and diabetes is coherent with our understanding of diabetes and there are other analogies. However the strength of association is weak, there is lack of consistency or specificity, and there is little evidence to support a biological gradient. We should therefore conclude that the evidence surrounding a causative link between antipsychotic drugs and diabetes is inconclusive. Moreover, the risk is probably low and the attributable risk of developing diabetes is greater for traditional risk factors such as family history, ethnicity, obesity and ageing than it is for receiving an antipsychotic drug. Consequently, the majority of patients receiving second-generation antipsychotics will not develop diabetes as a result of their medication.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Holt RIG, Bushe C, Citrome L (2005) Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol 19:56–65PubMedCrossRef Holt RIG, Bushe C, Citrome L (2005) Diabetes and schizophrenia 2005: are we any closer to understanding the link? J Psychopharmacol 19:56–65PubMedCrossRef
2.
Zurück zum Zitat Holt RIG, Peveler RC (2006) Anti-psychotic drugs and diabetes. Diabetes Obes Metab 8:125–135PubMedCrossRef Holt RIG, Peveler RC (2006) Anti-psychotic drugs and diabetes. Diabetes Obes Metab 8:125–135PubMedCrossRef
3.
Zurück zum Zitat Pus PE (2004) Vliv farmaceutickeho prumyslu na vzdelavani lekaru. Psychiatrie (Czech) 8:332 Pus PE (2004) Vliv farmaceutickeho prumyslu na vzdelavani lekaru. Psychiatrie (Czech) 8:332
4.
Zurück zum Zitat Stahl SM (2005) Detecting and dealing with bias in psychopharmacology. PsychEd Up 1:6–7 Stahl SM (2005) Detecting and dealing with bias in psychopharmacology. PsychEd Up 1:6–7
5.
Zurück zum Zitat Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychological Med 29:697–701CrossRef Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychological Med 29:697–701CrossRef
6.
Zurück zum Zitat Cheta D, Dumitrescu C, Georgescu M et al (1990) A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabetes Metab 16:11–15 Cheta D, Dumitrescu C, Georgescu M et al (1990) A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabetes Metab 16:11–15
7.
Zurück zum Zitat Mukherjee S, Schnur DB, Reddy R (1989) Family history of type 2 diabetes in schizophrenic patients. Lancet 1:495PubMedCrossRef Mukherjee S, Schnur DB, Reddy R (1989) Family history of type 2 diabetes in schizophrenic patients. Lancet 1:495PubMedCrossRef
8.
Zurück zum Zitat McCreadie R, Macdonald E, Blacklock C et al (1998) Dietary intake of schizophrenic patients in Nithsdale, Scotland: case–control study. BMJ 317:78–785 McCreadie R, Macdonald E, Blacklock C et al (1998) Dietary intake of schizophrenic patients in Nithsdale, Scotland: case–control study. BMJ 317:78–785
9.
Zurück zum Zitat Taylor D, Young C, Esop R, Paton C, Walwyn R (2004) Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 185:152–156PubMedCrossRef Taylor D, Young C, Esop R, Paton C, Walwyn R (2004) Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 185:152–156PubMedCrossRef
10.
11.
Zurück zum Zitat Subramaniam M, Chong SA, Pek E (2003) Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 48:345–347PubMed Subramaniam M, Chong SA, Pek E (2003) Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 48:345–347PubMed
12.
Zurück zum Zitat Hill AB (1965) The environment and disease; association or causation. Proc Royal Soc Med 58:295–330 Hill AB (1965) The environment and disease; association or causation. Proc Royal Soc Med 58:295–330
13.
Zurück zum Zitat Shakir SA, Layton D (2002) Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf 25:467–471PubMedCrossRef Shakir SA, Layton D (2002) Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf 25:467–471PubMedCrossRef
14.
Zurück zum Zitat Haddad PM (2004) Antipsychotics and diabetes: review of non-prospective data. Br J Psychiatry 47(Suppl):S80–S86CrossRef Haddad PM (2004) Antipsychotics and diabetes: review of non-prospective data. Br J Psychiatry 47(Suppl):S80–S86CrossRef
15.
Zurück zum Zitat Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA (2002) Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63:920–930PubMed Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA (2002) Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 63:920–930PubMed
16.
Zurück zum Zitat Gianfrancesco F, White R, Wang RH, Nasrallah HA (2003) Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 23:328–335PubMedCrossRef Gianfrancesco F, White R, Wang RH, Nasrallah HA (2003) Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 23:328–335PubMedCrossRef
17.
Zurück zum Zitat Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L (2003) A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 56:164–170PubMedCrossRef Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L (2003) A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 56:164–170PubMedCrossRef
18.
Zurück zum Zitat Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D (2003) Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 25:1150–1171PubMedCrossRef Gianfrancesco F, Grogg A, Mahmoud R, Wang RH, Meletiche D (2003) Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 25:1150–1171PubMedCrossRef
19.
Zurück zum Zitat Etminan M, Streiner DL, Rochon PA (2003) Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy 23:1411–1415PubMedCrossRef Etminan M, Streiner DL, Rochon PA (2003) Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy 23:1411–1415PubMedCrossRef
20.
Zurück zum Zitat Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J (2002) Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 22:236–243PubMedCrossRef Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J (2002) Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol 22:236–243PubMedCrossRef
21.
Zurück zum Zitat Koro CE, Fedder DO, L’Italien GJ et al (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case–control study. BMJ 325:243PubMedCrossRef Koro CE, Fedder DO, L’Italien GJ et al (2002) Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case–control study. BMJ 325:243PubMedCrossRef
22.
Zurück zum Zitat Kornegay CJ, Vasilakis-Scaramozza C, Jick H (2002) Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 63:758–762PubMed Kornegay CJ, Vasilakis-Scaramozza C, Jick H (2002) Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 63:758–762PubMed
23.
Zurück zum Zitat Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561–566PubMedCrossRef Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R (2002) Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561–566PubMedCrossRef
24.
Zurück zum Zitat Lund BC, Perry PJ, Brooks JM, Arndt S (2001) Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 58:1172–1176PubMedCrossRef Lund BC, Perry PJ, Brooks JM, Arndt S (2001) Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 58:1172–1176PubMedCrossRef
25.
Zurück zum Zitat Caro JJ, Ward A, Levinton C, Robinson K (2002) The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 63:1135–1139PubMed Caro JJ, Ward A, Levinton C, Robinson K (2002) The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 63:1135–1139PubMed
26.
Zurück zum Zitat Fuller MA, Shermock KM, Secic M, Grogg AL (2003) Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 23:1037–1043PubMedCrossRef Fuller MA, Shermock KM, Secic M, Grogg AL (2003) Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 23:1037–1043PubMedCrossRef
27.
Zurück zum Zitat Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A (2005) Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol:1–12 Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A (2005) Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol:1–12
28.
Zurück zum Zitat Taylor D, Young C, Mohamed R, Paton C, Walwyn R (2005) Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 19:182–186PubMedCrossRef Taylor D, Young C, Mohamed R, Paton C, Walwyn R (2005) Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 19:182–186PubMedCrossRef
29.
Zurück zum Zitat Citrome LL, Jaffe A, Levine J, Allingham B, Robinson J (2004) Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 55:1006–1013PubMedCrossRef Citrome LL, Jaffe A, Levine J, Allingham B, Robinson J (2004) Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 55:1006–1013PubMedCrossRef
30.
Zurück zum Zitat Barner JC, Worchel J, Yang M (2004) Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans. Pharmacotherapy 24:1529–1538PubMedCrossRef Barner JC, Worchel J, Yang M (2004) Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans. Pharmacotherapy 24:1529–1538PubMedCrossRef
31.
Zurück zum Zitat Leslie DL, Rosenheck RA (2004) Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 161:1709–1711PubMedCrossRef Leslie DL, Rosenheck RA (2004) Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 161:1709–1711PubMedCrossRef
32.
Zurück zum Zitat Ollendorf DA, Joyce AT, Rucker M (2004) Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. Med Gen Med 6:5 Ollendorf DA, Joyce AT, Rucker M (2004) Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. Med Gen Med 6:5
33.
Zurück zum Zitat Miller EA, Leslie DL, Rosenheck RA (2005) Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis 193:387–395PubMedCrossRef Miller EA, Leslie DL, Rosenheck RA (2005) Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis 193:387–395PubMedCrossRef
34.
Zurück zum Zitat Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W (2005) Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case–control study of California Medicaid claims. Pharmacoepidemiol Drug Saf 14:417–425PubMedCrossRef Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W (2005) Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case–control study of California Medicaid claims. Pharmacoepidemiol Drug Saf 14:417–425PubMedCrossRef
35.
Zurück zum Zitat Mackin P, Watkinson HM, Young AH (2005) Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48:215–221PubMedCrossRef Mackin P, Watkinson HM, Young AH (2005) Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48:215–221PubMedCrossRef
36.
Zurück zum Zitat Spoelstra JA, Stolk RP, Cohen D et al (2004) Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. J Clin Psychiatry 65:674–678PubMed Spoelstra JA, Stolk RP, Cohen D et al (2004) Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. J Clin Psychiatry 65:674–678PubMed
37.
Zurück zum Zitat Biswas PN, Wilton LV, Pearcel GL, Freemantle S, Shakir SA (2001) The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 15:265–271CrossRef Biswas PN, Wilton LV, Pearcel GL, Freemantle S, Shakir SA (2001) The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 15:265–271CrossRef
38.
Zurück zum Zitat Citrome LL (2004) The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today 40:445–464PubMedCrossRef Citrome LL (2004) The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs Today 40:445–464PubMedCrossRef
39.
Zurück zum Zitat Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO (2004) Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161:1837–1847PubMedCrossRef Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO (2004) Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 161:1837–1847PubMedCrossRef
40.
Zurück zum Zitat Kane JM (2003) Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. J Clin Psychiatry 64(Suppl 19):19–25PubMed Kane JM (2003) Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials. J Clin Psychiatry 64(Suppl 19):19–25PubMed
41.
Zurück zum Zitat Lieberman JA, Tollefson G, Tohen M et al (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396–1404PubMedCrossRef Lieberman JA, Tollefson G, Tohen M et al (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396–1404PubMedCrossRef
42.
Zurück zum Zitat McQuade RD, Stock E, Marcus R et al (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65(Suppl 18):47–56PubMed McQuade RD, Stock E, Marcus R et al (2004) A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 65(Suppl 18):47–56PubMed
43.
Zurück zum Zitat Bushe C, Holt R (2004) Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry (Suppl 47):S67–S71 Bushe C, Holt R (2004) Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry (Suppl 47):S67–S71
44.
Zurück zum Zitat Lieberman JA, Phillips M, Gu H et al (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacol 28:995–1003 Lieberman JA, Phillips M, Gu H et al (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacol 28:995–1003
45.
Zurück zum Zitat Lindenmayer JP, Czobor P, Volavka J et al (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160:290–296PubMedCrossRef Lindenmayer JP, Czobor P, Volavka J et al (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160:290–296PubMedCrossRef
46.
Zurück zum Zitat Torbeyns A, Marder S, Carson W et al (2004) Glycaemic control and plasma lipids in long term treatment with aripiprazole. Schizophrenia Res 67(Suppl):S192 Torbeyns A, Marder S, Carson W et al (2004) Glycaemic control and plasma lipids in long term treatment with aripiprazole. Schizophrenia Res 67(Suppl):S192
47.
Zurück zum Zitat Beasley CM Jr, Sutton VK, Hamilton SH et al (2003) A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 23:582–594PubMedCrossRef Beasley CM Jr, Sutton VK, Hamilton SH et al (2003) A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 23:582–594PubMedCrossRef
48.
Zurück zum Zitat Marder SR, McQuade RD, Stock E et al (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123–136PubMedCrossRef Marder SR, McQuade RD, Stock E et al (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123–136PubMedCrossRef
49.
Zurück zum Zitat Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223PubMedCrossRef Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223PubMedCrossRef
50.
Zurück zum Zitat Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP (2005) Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. Int J Neuropsychopharmacol:1–8 Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP (2005) Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. Int J Neuropsychopharmacol:1–8
51.
Zurück zum Zitat Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP (2004) A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 65:696–701PubMed Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP (2004) A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry 65:696–701PubMed
52.
Zurück zum Zitat McEvoy JP, Meyer JM, Goff DC et al (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19–32PubMedCrossRef McEvoy JP, Meyer JM, Goff DC et al (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80:19–32PubMedCrossRef
53.
Zurück zum Zitat Lorenz WF (1922) Sugar intolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry 8:184–196 Lorenz WF (1922) Sugar intolerance in dementia praecox and other mental disorders. Arch Neurol Psychiatry 8:184–196
54.
Zurück zum Zitat Appel KE, Farr CB (1929) Blood sugar reaction to insulin in psychoses. Arch Neurol Psychiatry 21:145–148 Appel KE, Farr CB (1929) Blood sugar reaction to insulin in psychoses. Arch Neurol Psychiatry 21:145–148
55.
Zurück zum Zitat Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284–289PubMedCrossRef Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284–289PubMedCrossRef
56.
Zurück zum Zitat Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R (2002) Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 26:137–141PubMedCrossRef Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R (2002) Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 26:137–141PubMedCrossRef
57.
Zurück zum Zitat Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184:58–62PubMedCrossRef Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184:58–62PubMedCrossRef
58.
Zurück zum Zitat Arranz B, Rosel P, Ramirez N et al (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65:1335–1342PubMed Arranz B, Rosel P, Ramirez N et al (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65:1335–1342PubMed
59.
Zurück zum Zitat Balter J, Mofsen R, Pinninti N (2004) Quetiapine in the successful treatment of psychosis and comorbid brittle diabetes mellitus: a case report. Int J Psychiatry Med 34:259–266PubMedCrossRef Balter J, Mofsen R, Pinninti N (2004) Quetiapine in the successful treatment of psychosis and comorbid brittle diabetes mellitus: a case report. Int J Psychiatry Med 34:259–266PubMedCrossRef
60.
Zurück zum Zitat Citrome L, Jaffe A, Levine J (2005) Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol 25:388–391PubMedCrossRef Citrome L, Jaffe A, Levine J (2005) Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol 25:388–391PubMedCrossRef
61.
Zurück zum Zitat Perry PJ, Argo TR, Carnahan RM et al (2005) The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 25:250–254PubMedCrossRef Perry PJ, Argo TR, Carnahan RM et al (2005) The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol 25:250–254PubMedCrossRef
62.
Zurück zum Zitat Haddad P (2005) Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 19:16–27PubMedCrossRef Haddad P (2005) Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 19:16–27PubMedCrossRef
63.
Zurück zum Zitat Allison DB, Mentore JL, Heo M et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696PubMed Allison DB, Mentore JL, Heo M et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696PubMed
64.
Zurück zum Zitat Lambert M, Haro JM, Novick D et al (2005) Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 111:232–243PubMedCrossRef Lambert M, Haro JM, Novick D et al (2005) Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand 111:232–243PubMedCrossRef
65.
Zurück zum Zitat Potkin SG, Saha AR, Kujawa MJ et al (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681–690PubMedCrossRef Potkin SG, Saha AR, Kujawa MJ et al (2003) Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681–690PubMedCrossRef
66.
Zurück zum Zitat Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S (2005) Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25:255–258PubMedCrossRef Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S (2005) Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 25:255–258PubMedCrossRef
67.
Zurück zum Zitat Jin H, Meyer JM, Jeste DV (2002) Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 14:59–64PubMed Jin H, Meyer JM, Jeste DV (2002) Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 14:59–64PubMed
68.
Zurück zum Zitat Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M (2004) Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 65:471–477PubMedCrossRef Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M (2004) Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 65:471–477PubMedCrossRef
69.
Zurück zum Zitat Sowell M, Mukhopadhyay N, Cavazzoni P et al (2003) Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 88:5875–5880PubMedCrossRef Sowell M, Mukhopadhyay N, Cavazzoni P et al (2003) Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 88:5875–5880PubMedCrossRef
70.
Zurück zum Zitat Sowell MO, Mukhopadhyay N, Cavazzoni P et al (2002) Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 87:2918–2923PubMedCrossRef Sowell MO, Mukhopadhyay N, Cavazzoni P et al (2002) Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 87:2918–2923PubMedCrossRef
71.
Zurück zum Zitat Engl J, Laimer M, Niederwanger A et al (2005) Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 10:1089–1096PubMedCrossRef Engl J, Laimer M, Niederwanger A et al (2005) Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 10:1089–1096PubMedCrossRef
72.
Zurück zum Zitat Ader M, Kim SP, Catalano KJ et al (2005) Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54:862–871PubMedCrossRef Ader M, Kim SP, Catalano KJ et al (2005) Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54:862–871PubMedCrossRef
73.
Zurück zum Zitat Baptista T, Alvarez L, Lacruz A, de Mendoza S, Hernandez L (1999) Glucose tolerance and serum insulin levels in an animal model of obesity induced by sub-acute or chronic administration of antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 23:277–287PubMedCrossRef Baptista T, Alvarez L, Lacruz A, de Mendoza S, Hernandez L (1999) Glucose tolerance and serum insulin levels in an animal model of obesity induced by sub-acute or chronic administration of antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 23:277–287PubMedCrossRef
74.
Zurück zum Zitat Bushe C, Paton C (2005) The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? J Psychopharmacol 19:76–83PubMedCrossRef Bushe C, Paton C (2005) The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? J Psychopharmacol 19:76–83PubMedCrossRef
75.
Zurück zum Zitat Melkersson K, Jansson E (2005) The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro. Neuro Endocrinol Lett 26:205–208PubMed Melkersson K, Jansson E (2005) The atypical antipsychotics quetiapine, risperidone and ziprasidone do not increase insulin release in vitro. Neuro Endocrinol Lett 26:205–208PubMed
76.
Zurück zum Zitat Avram AM, Patel V, Taylor HC, Kirwan JP, Kalhan S (2001) Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacotherapy 35:1381–1387CrossRef Avram AM, Patel V, Taylor HC, Kirwan JP, Kalhan S (2001) Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacotherapy 35:1381–1387CrossRef
77.
Zurück zum Zitat Jick H, Garcia Rodriguez LA, Perez-Gutthann S (1998) Principles of epidemiological research on adverse and beneficial drug effects. Lancet 352:1767–1770PubMedCrossRef Jick H, Garcia Rodriguez LA, Perez-Gutthann S (1998) Principles of epidemiological research on adverse and beneficial drug effects. Lancet 352:1767–1770PubMedCrossRef
Metadaten
Titel
Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria
verfasst von
R. I. G. Holt
R. C. Peveler
Publikationsdatum
01.07.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 7/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0279-3

Weitere Artikel der Ausgabe 7/2006

Diabetologia 7/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.